Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

211.61USD
25 Sep 2017
Change (% chg)

$6.96 (+3.40%)
Prev Close
$204.65
Open
$211.00
Day's High
$213.28
Day's Low
$208.07
Volume
914,316
Avg. Vol
513,481
52-wk High
$256.78
52-wk Low
$184.58

Latest Key Developments (Source: Significant Developments)

Allergan Plc Q2 revenue $4.0 billion
Thursday, 3 Aug 2017 07:52am EDT 

Aug 3 (Reuters) - Allergan Plc :Allergan reports continued strong execution in second quarter 2017 with 9% increase in GAAP net revenues to $4.0 billion.Q2 revenue $4.0 billion versus I/B/E/S view $3.94 billion.‍Q2 2017 GAAP continuing operations loss per share of $2.35​.Q2 non-GAAP performance net income per share of $4.02​.Company raises full-year 2017 continuing operations guidance​.Company recorded restructuring charges of $65.6 million in q2 of 2017​.Sees full year 2017 GAAP loss per share $10.80 - $11.20​.Sees total net revenues in FY 2017 of $15,850 million - $16,050 million.Sees FY non GAAP earnings per share ‍$16.05 - $16.45​.FY2017 earnings per share view $16.08, revenue view $15.80 billion -- Thomson Reuters I/B/E/S.Q2 earnings per share view $3.92 -- Thomson Reuters I/B/E/S.  Full Article

Allergan Q3 cash dividend of $0.70/shr
Wednesday, 2 Aug 2017 08:00am EDT 

Aug 2 (Reuters) - Allergan Plc :Allergan announces third quarter 2017 cash dividend of $0.70 per ordinary share.  Full Article

Amgen and Allergan submit biosimilar Biologics License application for ABP 980 to U.S. FDA
Monday, 31 Jul 2017 09:00am EDT 

July 31 (Reuters) - Amgen Inc :Amgen and Allergan submit biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration.Amgen - Co and Allergan are collaborating on four oncology biosimilar medicines, including ABP 980 which is second to be submitted for FDA approval​.  Full Article

Allergan submits investigational NDA for rtgel in combination with botox
Wednesday, 19 Jul 2017 08:30am EDT 

July 19 (Reuters) - Urogen Pharma Ltd ::Investigational new drug application for rtgel™ in combination with botox® for the treatment of overactive bladder submitted to FDA by Allergan.Says it will receive a milestone payment of $7.5 million under its exclusive worldwide licensing agreement with allergan.Urogen Pharma - milestone payment resulting from Allergan's submission of investigational new drug application for rtgel in combination with botox to U.S. FDA.  Full Article

Amgen, Allergan to discuss data supporting biologics license application for ABP 215
Thursday, 13 Jul 2017 08:00am EDT 

July 13 (Reuters) - Allergan Plc :Amgen and allergan to discuss data supporting biologics license application for abp 215, a biosimilar candidate to avastin® (bevacizumab).Amgen inc- ‍fda has set a biosimilar user fee act (bsufa) target action date of sept. 14, 2017, for abp 215​.Amgen inc- ‍co, allergan will discuss data supporting abp 215 bla with oncologic drugs advisory committee of u.s. fda​.  Full Article

Allergan announces launch of artificial tear refresh optive mega-3
Tuesday, 27 Jun 2017 08:00am EDT 

June 27 (Reuters) - Allergan Plc ::Allergan plc - announced launch of over-the-counter artificial tear refresh optive mega-3.  Full Article

Allergan to acquire Keller Medical, adding Keller Funnel to co's leading plastic surgery portfolio
Wednesday, 7 Jun 2017 08:30am EDT 

June 7 (Reuters) - Allergan Plc :Allergan to acquire Keller Medical, Inc., adding Keller Funnel® to company's leading plastic surgery portfolio.  Full Article

Allergan announces closing of public offering
Friday, 26 May 2017 07:00am EDT 

May 26 (Reuters) - Allergan Plc ::Allergan announces closing of public offering of senior notes to refinance existing debt.  Full Article

Allergan prices public offering of senior notes to refinance existing debt
Tuesday, 23 May 2017 05:30pm EDT 

May 23 (Reuters) - Allergan Plc :Allergan announces pricing of public offering of senior notes to refinance existing debt.Allergan plc - has priced an offering of eur 2.7 billion aggregate principal amount of senior unsecured notes in 4 tranches.Allergan plc - notes will be issued by its indirect wholly-owned subsidiary, allergan funding scs.  Full Article

Carl Icahn dissolves shared share stake in Allergan
Monday, 15 May 2017 05:59pm EDT 

May 15 (Reuters) - Carl Icahn::Carl Icahn dissolves share stake in Allergan Plc - sec filing.Carl Icahn takes shared share stake of 10.6 million shares in Welbilt Inc.Carl Icahn holdings cited is Icahn's shared share stake in the respective companies.Carl Icahn - change in holdings are as of March 31, 2017 and compared with the previous quarter ended as of Dec 31, 2016.  Full Article

Photo

Allergan boosts shares with $2 billion buyback

U.S. drugmaker Allergan Plc on Monday authorized a $2 billion buyback of its common stock, sending its shares up after a week of disappointing news on its drug development pipeline.